Syngenta filed a new motion on June 4, 2026, to remove paraquat litigation from Philadelphia Court of Common Pleas—a direct sequel to a similar challenge the company lost in 2025. The motion targets over 1,600 Pennsylvania-based claims alleging paraquat exposure caused Parkinson’s disease, arguing that non-Pennsylvania residents should not be permitted to file in the state and that the caseload creates undue burden on Philadelphia courts. This is Syngenta’s second attempt to disperse paraquat claims across different jurisdictions, a strategy that Judge Joshua Roberts previously rejected as “cherry-picked” venue selection designed to scatter cases nationwide.
The timing matters. With 1,843 total plaintiffs in the Philadelphia court and over 1,100 cases still pending as of June 2026, Syngenta is escalating efforts to move litigation away from a venue where it has already lost one major procedural battle. The company faces parallel litigation in federal court—specifically in the MDL 3004 docket in Southern District of Illinois, where over 6,651 cases are pending under Judge Nancy J. Rosenstengel—and the company appears intent on fragmenting the Philadelphia cases before they advance further.
Table of Contents
- Why Is Syngenta Filing Another Venue Motion After Its First One Failed?
- What Did Judge Roberts Say About the Previous Venue Motion?
- How Many Cases Are Actually Pending in Philadelphia?
- How Does the Federal MDL Fit Into This Venue Battle?
- What Is the Role of the Master Settlement Agreement in This Motion?
- Why Did Syngenta Announce a Paraquat Phase-Out in March 2026?
- What Happened to the Bellwill Settlement, and What Does It Signal?
Why Is Syngenta Filing Another Venue Motion After Its First One Failed?
Syngenta and Chevron previously filed a motion in 2025 to transfer over 900 paraquat cases out of Philadelphia. Judge Joshua Roberts denied that motion, ruling that defendants had improperly attempted to “scatter those cases to jurisdictions across the country” using what he called a “cherry-picked” approach to venue selection. Despite this clear judicial rejection, Syngenta has returned with a nearly identical argument: that out-of-state plaintiffs should not be permitted to litigate in Philadelphia, and that the court faces administrative burden.
The practical difference between the two motions lies in scope and strategy. The 2025 motion targeted roughly 900 cases; the June 2026 filing addresses 1,600-plus claims—a larger volume that may suggest Syngenta believes a bigger venue challenge will succeed where a smaller one failed. Additionally, Syngenta may be betting that the composition of pending cases or changes in Pennsylvania law between 2025 and 2026 create new legal arguments. However, Judge Roberts’ previous ruling established a clear precedent that defendant preference for dispersed litigation is not sufficient grounds for venue transfer in mass tort contexts.
What Did Judge Roberts Say About the Previous Venue Motion?
Judge Joshua Roberts’ 2025 ruling directly characterized Syngenta and Chevron’s strategy as inappropriate. He stated that defendants were using venue selection rules not as a neutral framework but as a weapon to prevent consolidated litigation. By seeking to move cases to “jurisdictions across the country,” the defendants were attempting to avoid the efficiencies and oversight that come with centralized case management. This ruling is not merely advisory—it is binding precedent in the Philadelphia Court of Common Pleas and will likely influence how the June 2026 motion is evaluated.
One critical limitation of Roberts’ prior ruling, however, is that it does not prevent Syngenta from refiling. The company clearly believes either that new legal arguments or changed circumstances warrant another attempt. Defense lawyers may argue, for instance, that the Pennsylvania-specific claims are distinct from non-Pennsylvania claims and should be severed. They may also cite administrative data showing increased court docket congestion since the 2025 ruling. Judge Roberts will be forced to distinguish between defending his prior logic and responding to genuinely new factual or legal developments—a distinction that favors defendants if circumstances have materially changed.
How Many Cases Are Actually Pending in Philadelphia?
As of June 2026, the Philadelphia Court of Common Pleas has 1,843 total plaintiffs with over 1,100 cases still pending. This number is substantial enough to create genuine administrative pressure on a single court system, particularly in a state court setting where judicial resources are often more constrained than in federal courts. Syngenta’s argument that this volume creates an “administrative burden” is not frivolous—a judge juggling 1,100 paraquat cases must also manage other civil litigation, creating real scheduling and resource challenges. However, the administrative burden argument cuts both ways.
Dispersing 1,100 cases across multiple jurisdictions creates fragmentation, inconsistent rulings, and duplicative discovery—all of which ultimately impose *greater* administrative burden on the overall judicial system. Philadelphia’s centralized approach allows Judge Roberts to issue unified scheduling orders, harmonize discovery disputes, and prevent inconsistent outcomes on identical legal questions. For plaintiffs, this creates predictability; for the court system as a whole, it improves efficiency. Syngenta’s characterization of Philadelphia as “burdened” ignores the comparative burden that would result from the remedy the company is seeking.
How Does the Federal MDL Fit Into This Venue Battle?
Paraquat litigation exists on two parallel tracks: the state court docket in Philadelphia and the federal MDL 3004 in the Southern District of Illinois, which houses 6,651 pending cases. These are not the same cases—plaintiffs choose whether to file in state or federal court, and the Master Settlement Agreement executed in September 2025 formalized opt-in and opt-out mechanisms for both forums. The existence of a much larger federal docket (6,651 cases vs. 1,100 in Philadelphia state court) actually complicates Syngenta’s administrative burden argument.
If Syngenta succeeds in moving cases out of Philadelphia, those cases will likely flow into the federal MDL, which is already managing thousands of paraquat claims under centralized Judge Nancy J. Rosenstengel’s oversight. Moving Pennsylvania state cases into the federal system would not reduce administrative burden—it would increase Judge Rosenstengel’s docket. Alternatively, if cases are scattered across multiple state jurisdictions, then plaintiffs face the disadvantage of inconsistent discovery rulings, conflicting summary judgment standards, and potentially divergent trial outcomes. This tradeoff—centralized burden on one judge versus fragmented burden across many judges—is one reason prior courts have rejected similar venue challenges in other mass torts.
What Is the Role of the Master Settlement Agreement in This Motion?
In September 2025, Syngenta executed a Master Settlement Agreement with paraquat plaintiffs, establishing a framework for claim resolution and settlement value distribution. This MSA fundamentally changed the litigation landscape by codifying which claims are eligible for settlement, what claim values should be (based on disease staging), and which plaintiffs can participate. One critical implication: once an MSA is executed, venue arguments become less about litigation strategy and more about settlement administration.
A warning about timing is warranted here. Syngenta’s June 2026 motion—filed months *after* the MSA was finalized—may be interpreted by Judge Roberts as an attempt to circumvent settlement obligations by making litigation in Philadelphia so administratively difficult that plaintiffs are forced to settle on unfavorable terms. Defense motions filed after settlement agreements are in place can trigger sanctions or adverse inferences if the court believes the motions are dilatory tactics rather than good-faith procedure. Judge Roberts will likely consider whether this motion serves legitimate venue management or whether it is instead a pressure tactic designed to weaken plaintiffs’ negotiating position during settlement administration.
Why Did Syngenta Announce a Paraquat Phase-Out in March 2026?
In March 2026, Syngenta announced a plan to phase out paraquat production. This announcement occurred just three months *before* the June 4 venue motion, suggesting that Syngenta may be attempting to create a narrative of corporate cooperation and responsibility. By announcing a production phase-out, the company can argue that future paraquat exposure is no longer possible—a fact that could theoretically reduce the urgency of consolidated litigation.
However, this argument has a built-in weakness: the phase-out does not remediate prior exposure or resolve pending claims. From a litigation strategy perspective, the phase-out announcement may also signal to Judge Roberts that Syngenta is attempting to minimize the importance of the Philadelphia docket. If Syngenta convinces the court that paraquat is being phased out and future claims are unlikely, the company can argue that large centralized case management is unnecessary. Plaintiffs will counter that existing exposure claims still require fair and consistent treatment, and that the phase-out is merely a business decision unrelated to defendants’ legal obligations to pay damages for prior wrongdoing.
What Happened to the Bellwill Settlement, and What Does It Signal?
On January 27, 2026, a bellwill trial in the paraquat litigation settled before trial commenced. A bellwill trial is a representative case chosen to test the strengths and weaknesses of claims before full-scale litigation.
The fact that Syngenta settled the bellwill case before trial suggests that the company faced significant liability exposure and preferred to resolve early rather than risk a jury verdict. This settlement may paradoxically undermine Syngenta’s venue argument: if the company believes paraquat claims lack merit, why did it settle a bellwill case at all? The bellwill settlement also establishes a baseline for settlement value that Judge Roberts will reference when evaluating whether Syngenta’s current venue motion is motivated by good-faith efficiency concerns or by a desire to avoid centralized litigation. Defendants typically cite efficiency arguments when facing strong cases; when facing weak cases, venue fragmentation serves the company’s interests because weak claims in multiple jurisdictions may settle for lower values individually than they would if consolidated.